NeoGenomics (NASDAQ: NEO) COO sells 22,128 shares at $12.5037

Rhea-AI Filing Summary

NeoGenomics Inc. President & Chief Operating Officer Stone Warren reported a sale of company stock. On January 20, 2026, he sold 22,128 shares of common stock at a price of $12.5037 per share, leaving him with 121,631 common shares owned directly.

The filing also lists his existing equity awards, including stock options and restricted and performance stock units granted between 2022 and 2025. These include options to buy 166,113 shares at $11.21 exercisable until December 1, 2029, and additional option grants such as 143,266 options and 94,518 options that vest in stages over two years. He also holds sizable restricted stock unit and performance stock unit awards, such as 84,317, 59,382, and 52,687 share-equivalent RSU positions, with vesting tied to continued service and, for performance units, to share price and revenue growth goals. Some options were granted at a premium exercise price set at 110% of the stock’s closing price on specified grant dates.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stone Warren

(Last) (First) (Middle)

9490 NEOGENOMICS WAY

(Street)

FORT MYERS FL 33912

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEOGENOMICS INC [ NEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres & Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		22,128	D	$12.5037	121,631	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.21							(1)	12/01/2029	Common Stock	166,113		166,113	D
Stock Option (Right to Buy)	$19.65							(2)	05/11/2030	Common Stock	53,969		53,969	D
Performance Stock Unit	$0							05/11/2026(3)	(4)	Common Stock	21,204		21,204	D
Restricted Stock Unit	$0							(5)	(4)	Common Stock	9,613		9,613	D
Stock Option (Right to Buy)	$16.45							(6)	02/23/2034	Common Stock	42,344		42,344	D
Restricted Stock Unit	$0							(7)	(4)	Common Stock	16,886		16,886	D
Performance Stock Unit	$0							02/23/2027(8)	(4)	Common Stock	25,330		25,330	D
Stock Option (Right to Buy)	$13.96							(9)	05/02/2034	Common Stock	29,976		29,976	D
Restricted Stock Unit	$0							(10)	(4)	Common Stock	17,908		17,908	D
Performance Stock Unit	$0							05/02/2027(11)	(4)	Common Stock	17,908		17,908	D
Restricted Stock Unit	$0							01/13/2026	(4)	Common Stock	59,382		59,382	D
Stock Option (Right to Buy)	$13.05(12)							(13)	02/21/2035	Common Stock	143,266		143,266	D
Restricted Stock Unit	$0							(14)	(4)	Common Stock	84,317		84,317	D
Stock Option (Right to Buy)	$10.44(15)							(16)	04/01/2035	Common Stock	94,518		94,518	D
Restricted Stock Unit	$0							(17)	(4)	Common Stock	52,687		52,687	D

Explanation of Responses:

1. On December 1, 2022, Mr. Stone was granted 166,113 stock options. The options vest ratably over the first four anniversary dates of the grant date.

2. On May 11, 2023, Mr. Stone was granted 53,969 stock options. The options vest ratably over the first three anniversary dates of the grant date.

3. On May 11, 2023, Mr. Stone was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is31,806. The number of performance stock units that may vest is based on the achievement of certain growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.

4. Once vested, the shares of common stock are not subject to expiration.

5. On May 11, 2023, Mr. Stone was granted 28,838 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

6. On February 23, 2024, Mr. Stone was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.

7. On February 23, 2024, Mr. Stone was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

8. On February 23, 2024, Mr. Stone was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.

9. On May 2, 2024, Mr. Stone was granted 29,976 stock options. The options vest ratably over the first three anniversary dates of the grant date.

10. On May 2, 2024, Mr. Stone was granted 17,905 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

11. On May 2, 2024, Mr. Stone was granted 17,908 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is26,862. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.

12. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%

13. On February 21, 2025, Mr. Stone was granted 143,266 stock options. At the time of the grant, the options vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone's promotion to President &Chief Operating Officer on April 1, 2025, the vesting schedule of these options was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.

14. On February 21, 2025, Mr. Stone was granted 84,317 restricted stock units. At the time of the grant, the restricted stock units vested ratably over the first three anniversary dates of the grant date. In connection with Mr. Stone'spromotion to President & Chief Operating Officer on April 1, 2025, the vesting schedule of these restricted stock units was modified so that they now vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grantdate.

15. This stock option was granted as a premnium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.

16. On April 1, 2025, Mr. Stone was granted 94,518 stock options. The options vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.

17. On April 1, 2025, Mr. Stone was granted 52,687 restricted stock units. The restricted stock units vest ratably on the 12-month, 18-month and 24-month anniversary dates of the grant date.

Remarks:

	/s/ Ali Olivo, Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NeoGenomics (NEO) report for Stone Warren?

The filing reports that President & Chief Operating Officer Stone Warren sold 22,128 shares of NeoGenomics common stock on January 20, 2026.

At what price did Stone Warren sell NeoGenomics (NEO) shares?

Stone Warren sold the 22,128 NeoGenomics common shares at a price of $12.5037 per share.

How many NeoGenomics (NEO) shares does Stone Warren own after the sale?

After the reported transaction, Stone Warren directly owns 121,631 shares of NeoGenomics common stock.

What stock options does Stone Warren hold in NeoGenomics (NEO)?

He holds several option grants, including 166,113 options at $11.21 expiring on December 1, 2029, plus additional grants of 53,969, 42,344, 29,976, 143,266, and 94,518 options with vesting over multi-year periods.

What restricted and performance stock units does Stone Warren have at NeoGenomics (NEO)?

The filing lists multiple awards, including restricted stock units of 9,613, 16,886, 17,908, 59,382, 84,317, and 52,687 shares, and performance stock units of 21,204, 25,330, and 17,908 shares at target performance levels.

How do Stone Warren’s NeoGenomics (NEO) performance stock units vest?

His performance stock units may vest based on share price growth goals measured using a 20-day trailing average and on revenue growth goals, in each case subject to continued service with NeoGenomics.

What is notable about some of Stone Warren’s NeoGenomics (NEO) stock options?

Some options were granted as premium-price stock options, with exercise prices set at 110% of NeoGenomics’ closing share price on the referenced grant dates.